Neurotech International Limited provided the following update with respect to its upcoming Phase I/II open label study to evaluate the safety and efficacy of orally administered NTI/DOLCE full spectrum medicinal cannabis plant extract in children with Autism Spectrum Disorder ("ASD"). Preparations are almost complete for NTI to commence its first human clinical trial focussed on paediatric patients suffering from ASD. The trial will be a Phase I/II open label study to evaluate the safety and efficacy of orally administered NTI/DOLCE full spectrum medicinal cannabis plant extract. Importantly, this will be a world first trial assessing full spectrum (multiple cannabinoid) plant with less than 0.3% THC for children (aged 5 to 17) with ASD. The Company has completed a number of key steps, including: Completing trial design and protocols. Development of a final formulation for treatment delivery to patients. Development of a number of electronic data collection systems that will be used throughout the study to capture real time data including electronic psychologist assessments and electronic auditing and patient compliance systems to ensure patient compliance is achieved and patient feedback is continuously received.